Thrilled to have been part of Destination Startup hosted by Venture Partners at CU Boulder! Reglagene's CEO, Richard Austin, captivated a full room at 1:00 PM MDT with an exciting presentation focused on business and scientific milestones. A big thank you to Tech Launch Arizona for the invitation and to Stephen Miller for coordinating this fantastic event!

Reglagene's lead product, RGN6024, was accepted into TMC's Accelerator for Cancer Therapeutics. Find the full announcement below or on the EIN Presswire.

Pitching to a full house during Reglagene's presentation at BIO CEO & Investor Conference, in Times Square, New York City!

Last week, Teri Suzuki, Lilian Patrón, and Michael Abrahamson participated in the 16th Annual BIO5/BIOSA Student Industry Networking Event.

Reglagene's lead product, RGN6024, has received an exclusive orphan drug designation from the FDA. Read the full announcement here, or on the EIN Presswire.

What a week at JP Morgan Healthcare! Met amazing investors and service providers, fueling Reglagene's journey in developing innovative brain therapies.

We’re proud to share the news that Reglagene has completed a $5.4M private placement of its convertible preferred stock. With the support of our investors and partners, we’re well equipped to take the next steps in the development of our orally administered therapy, RGN6024. Read the full press release below or on the EIN PressWire.

Michael Abrahamson, an alumnus of the R. Ken Coit School of Pharmacy, presented his insights on personal growth and the value of making diverse connections after pharmacy school.